RT Book, Section
A1 Oppong, Samuel A.
A1 Stewart, Jodi-Anne
A1 DeBaun, Michael R.
A2 Gladwin, Mark T.
A2 Kato, Gregory J.
A2 Novelli, Enrico M.
SR Print(0)
ID 1179342711
T1 Management of Pregnant Women and Newborns With Sickle Cell Disease
T2 Sickle Cell Disease
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260458596
LK hemonc.mhmedical.com/content.aspx?aid=1179342711
RD 2023/12/08
AB Pregnant  women  with  sickle  cell  disease  experience  significant  morbidity  and  mortality  compared  to  the  general  population  in  both  low-middle  and  high-income  settings.  Women  with  sickle  cell  disease  are  more  likely  to  experience  hypertensive  emergencies  (preeclampsia  and  eclampsia),  intrauterine  growth  restriction  (IUGR),  low  birth  weight,  fetal  demise,  venous  thromboembolism,  peripartum  cardiomyopathy,  and  maternal  death  when  compared  to  age-matched  healthy  pregnant  women  in  both  low-middle–  and  high-income  settings.1-5